Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Biogen Idec concurs with FDA on safety monitoring for Gilenya through REMS

Biogen Idec is committed to improving the lives of people with multiple sclerosis (MS), and no company is doing more for these patients. There has been a desire within the MS community for an oral treatment for a long time, and the approval of Gilenya has made this a reality.

23 Sep 2010

Evotec AG collaborates with Almirall for ion channel validation in respiratory diseases

Evotec AG today announced that it has entered into a collaboration with Almirall S.A. to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases.

23 Sep 2010

FDA approves Gilenya capsules for reducing MS relapses

The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).

22 Sep 2010

Researchers receive $634,000 grant to study environmental factors, MS progression

A $634,000 grant from the Department of Defense is allowing researchers at the University at Buffalo to investigate a trio of environmental factors and their influence on the progression of multiple sclerosis.

22 Sep 2010

Phenex Pharmaceuticals announces closure of Series C financing round

Phenex Pharmaceuticals AG, a drug discovery and development company headquartered in Ludwigshafen, Germany, today announced the closure of its Series C financing round with a volume of 6 M € (7,8 M USD) bringing the total amount of funds raised to 17,2 M € (22,4 M USD).

21 Sep 2010

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from a 36-week active extension study evaluating two doses of laquinimod, an investigational, once-daily oral immunomodulator, for the treatment of relapsing remitting multiple sclerosis.

21 Sep 2010

Scientists identify new pathway to control immune balance

St. Jude Children's Research Hospital scientists have identified a new pathway that helps control the immune balance through reciprocal regulation of specialized T lymphocytes, which play very different inflammatory roles.

21 Sep 2010

Arrayit installs microarray platform at NIH

Arrayit Corporation has completed installation and technical training of its proprietary microarray platform at the National Institute of Mental Health, National Institutes of Health, in Rockville, Maryland. In 2010, the NIH will invest more than $31.2 billion in medical research for the American people through 50,000 competitive grants to 325,000 researchers at 3,000 universities, hospitals, companies, medical schools and scientific institutions in the United States and around the world.

21 Sep 2010

Public health at risk as Vitamin D evidence mounts

A group of prevention-focused healthcare organizations has expressed deep concern over recently-proposed restrictions to OHIP coverage of Vitamin D testing in the province. The proposed new legislation will delist OHIP insured Vitamin D testing for most Ontarians. Exceptions will be made for those with osteoporosis, malabsorption syndromes, and individuals taking medications that interfere with vitamin D absorption or metabolism.

21 Sep 2010

Intravenous aspirin safe, effective option for severe headache or migraine

A new study shows that aspirin, given intravenously (IV), may be a safe and effective option for people hospitalized for severe headache or migraine, undergoing medication withdrawal. The research will be published in the September 21, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

21 Sep 2010

Chronix Biomedical completes Series E financing

Chronix Biomedical today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix's serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.

20 Sep 2010

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic resistant infections, delivered four poster presentations on its Aganocide compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA.

16 Sep 2010

Same brain lesions associated with dementia responsible for mild memory loss in old age

New research suggests that old age may not play a role in why older people become forgetful. According to a study published in the September 15, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology, the same brain lesions that are associated with dementia are responsible for mild memory loss in old age.

16 Sep 2010

GSK, Genmab to refocus on ofatumumab development program in autoimmune indications

GlaxoSmithKline and Genmab A/S Following the 1st July announcement by GSK and Genmab of an amendment to the collaborative agreement for ofatumumab in which GSK assumed development responsibility for autoimmune indications, GSK and Genmab announced today plans to refocus the development program of ofatumumab in autoimmune indications.

16 Sep 2010

Novel Compound's NVC-422 broad-spectrum antimicrobial agent kills P. mirabilis bacteria in catheters

Patients fitted with long-term bladder catheters often face a potentially serious complication caused by a Gram-negative bacteria Proteus mirabilis that can colonize the catheters.

16 Sep 2010

COTI selected for Canadian life sciences partnering mission

Critical Outcome Technologies Inc. announced today that the Company was selected by the Consulate General of Canada and BIOTECanada to attend a life sciences partnering mission in Boston, MA. This initiative is being held in conjunction with the BioPharm America conference taking place September 15-17, 2010.

15 Sep 2010

AVANIR's AVP-923 Phase III STAR trial results published in 'Annals of Neurology' website

AVANIR Pharmaceuticals, Inc. today announced the electronic publication of the results of the pivotal Phase III STAR trial of its investigational drug AVP-923 (dextromethorphan/quinidine) in the Annals of Neurology. The publication entitled "Dextromethorphan Plus Ultra-Low-Dose Quinidine Reduces Pseudobulbar Affect" evaluated two low dose formulations compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).

15 Sep 2010

First Edition: September 14, 2010

Among today's headlines, Berwick talks, health reform politics continue and coverage of the run up to Sept. 23 - the day several health overhaul provisions take effect - is in full swing.

14 Sep 2010

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.

14 Sep 2010

Repetitive transcranial magnetic stimulation helps to regain motor function in partially paralyzed patients

Stroke patients who were left partially paralysed found that their condition improved after they received a simple and non-invasive method of brain stimulation, according to research in the September issue of the European Journal of Neurology.

14 Sep 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Biogen Idec concurs with FDA on safety monitoring for Gilenya through REMS

Evotec AG collaborates with Almirall for ion channel validation in respiratory diseases

FDA approves Gilenya capsules for reducing MS relapses

Researchers receive $634,000 grant to study environmental factors, MS progression

Phenex Pharmaceuticals announces closure of Series C financing round

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Scientists identify new pathway to control immune balance

Arrayit installs microarray platform at NIH

Public health at risk as Vitamin D evidence mounts

Intravenous aspirin safe, effective option for severe headache or migraine

Chronix Biomedical completes Series E financing

NovaBay Pharmaceuticals delivers poster presentations on Aganocide compound at ICAAC Conference

Same brain lesions associated with dementia responsible for mild memory loss in old age

GSK, Genmab to refocus on ofatumumab development program in autoimmune indications

Novel Compound's NVC-422 broad-spectrum antimicrobial agent kills P. mirabilis bacteria in catheters

COTI selected for Canadian life sciences partnering mission

AVANIR's AVP-923 Phase III STAR trial results published in 'Annals of Neurology' website

First Edition: September 14, 2010

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

Repetitive transcranial magnetic stimulation helps to regain motor function in partially paralyzed patients

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in